Serum institute likely to launches Covovax vaccine for children and adults by early 2022

Pune, Aug 07:  One of the world’s largest Vaccine manufacturer  Pharmaceutical company in Pune,Serum Institute of India (SII) CEO Mr.Adar C. Poonawala on Monday gave statement that they are hopeful of launching Covovax vaccine for adults in October this year and for children in Quarter 1 of 2022. He said it is subject to approval by the Drug Controller General of India (DCGI).

Poonawalla said, “While vaccines for children aged above 12 are likely by October, vaccine for those below 12 are likely by first quarter of 2022. At the time of launch (of Covovax), everyone will get to know the cost of the vaccine.”

Poonawalla thanked the government for its support and said the previous financial crisis during the procurement of raw materials in abundance is no more.

The government is always helping us; we’re thankful to PM Modi for all cooperation, support,” Poonawalla said after meeting Home Minister Amit Shah.

Poonawalla also met Union Health Minister Mansukh Mandaviya in Delhi and held a discussion over the supply of Covishield vaccine.

“We had many good meetings here. We discussed ramping up vaccine production. More than 17 countries in Europe have already approved Covishield and many are in line to give approval. We discussed also this. This will be good news for all the travellers also. We were doing what we can do for our students,” Poonawalla told news agency ANI after the meeting with Union Health Minister.

As per a government note, “In August the vaccine projection of Covaxin will be 2.65 crores, Covishield will be 23 crores and total a 25.65 crore doses will be produced in the month. In September the projection of Covaxin is 3.15 crore and Covishield will be 23 crores, which in total will be 26.15 crore doses. In October the total of 28.25 crore doses will be produced out of which Covaxin will be 5.25 crore and Covishield will be 23 crore doses